Background and purpose Cancer stem cells exhibit distinctive cellular metabolism compared with the more differentiated counterparts or normal cells. We aimed to investigate the impact of a novel radionuclide anti-cancer agent188Re-Liposome on stemness markers' expression and cellular metabolism in an ovarian cancer model. Material and methods A 2 × 2 factorial experiment was designed in which factor 1 represented the drug treatment comparing188Re-BMEDA, a free form of188Re, with188Re-Liposome, a nanoparticle-encapsulated form of188Re. Factor 2 represented the delivery route, comparing intravenous with intraperitoneal delivery. Results Intraperitoneal delivery of188Re-Liposome predominantly killed the CSCs-like cells in tumours and switched metabolism from glycolysis to oxidative phosphorylation. Further, intraperitoneal delivery of188Re-Liposome treatment was able to block epithelial-to-mesenchymal transition (EMT) and reactivate p53 function. Collectively, these molecular changes led to a striking tumour-killing effect. Conclusions Radionuclides encapsulated in liposomes may represent a novel treatment for ovarian cancer when delivered intraperitoneally (a type of loco-regional delivery). In the future, this concept may be further extended for the treatment of several relevant cancers that have been proved to be suitable for loco-regional delivery of therapeutic agents, such as colon cancer, gastric cancer, and pancreatic cancer.
- 188 Re
- Cancer stem cell
- Metabolic reprogramming
ASJC Scopus subject areas
- Radiology Nuclear Medicine and imaging